Up to $9.5 Million in Debt Financing and $12 Million in Equity Financing.
Company to Advance its Immuno-Dermatology and Inflammatory Bowel Disease Product Candidates
Lead Compound Bertilimumab, First-in-Class Autoimmune Therapy, a Priority
[…]
NASDAQ:EDUC […]
Will Also Participate in Additional Wattenberg Well […]
Wall Street Analyzer’s CEO Interview Series […]
(CSE: MRM, OTCQX: MMTIF) […]
First Product, the FieldServer EZ Gateway Modbus to BACnet, Rapidly Connects Modbus Devices to BACnet Management Systems […]
Wall Street Analyzer’s CEO Interview Series […]
(TSX: NB, OTCQX: NIOBF,FSE: BR3) […]
(TSX: NB, OTCQX: NIOBF, FSE: BR3) […]
Copyright © 2019 The Wall Street Analyst, LLC. All rights reserved. Website by MyWebsiteSpot.com